Immunoglobulin G4 (IgG4) is a subclass of immunoglobulin G, characterized by its unique structure and function in the immune response. The specific substance you mentioned, anti-(human complement C1s) IgG4, is a humanized mouse monoclonal antibody designed to target the human complement component C1s, which plays a crucial role in the complement system, a part of the immune system that enhances the ability to clear pathogens. This antibody is engineered to have a γ4 heavy chain and a κ light chain, forming a dimeric structure through disulfide bonds, which contributes to its stability and functionality. IgG4 is known for its anti-inflammatory properties and is less likely to activate complement compared to other IgG subclasses, making it suitable for therapeutic applications where modulation of the immune response is desired. The specificity of this antibody allows for targeted therapeutic interventions in conditions where complement activation is implicated, such as autoimmune diseases or certain inflammatory disorders.

Immunoglobulin G4, anti-(human complement C1s) (humanized mouse monoclonal TNT009 γ4-chain), disulfide with humanized mouse monoclonal TNT009 κ-chain, dimer

2049079-64-1: Immunoglobulin G4, anti-(human complement C1s) (humanized mouse monoclonal TNT009 γ4-chain), disulfide with humanized mouse monoclonal TNT009 κ-chain, dimer, Sutimlimab-jome, Enjaymo, Sutimlimab

Sutimlimab: monoclonal antibody, inhibits complement protein C1, treats cold agglutinin-induced hemolysis.

CAS 2049079-64-1: Immunoglobulin G4, anti-(human complement C1s) (humanized mouse monoclonal TNT009 γ4-chain), disulfide with humanized mouse monoclonal TNT009 κ-chain, dimer

Sutimlimab

Ref: TM-T76702

Sutimlimab

Ref: 3D-CLA1512